High concentrated probiotics improve inflammatory bowel diseases better than commercial concentration of probiotics

Abstract

The incidence of inflammatory bowel diseases has increased during recent decades in Korea as well as Asian countries. Probiotics have been clinically administered to improve intestinal inflammation in inflammatory bowel disease (IBD). In this study, we identified that higher concentrations of probiotics called "Amanlac" probiotics protected intestinal tissues with the regulation of cytokine production and the improvement of intestinal injury of mice with dextran sodium sulfate (DSS)-induced colitis much better than commercial probiotics. "Amanlac" probiotics significantly ameliorated gross and pathological scores of colitis caused by DSS in a concentration- dependent manner based on the following mechanisms; inflammatory markers such as IL-1β, TNF α and COX-2, as well as MMPs and ICAM1 were significantly lower in colon tissues of probiotics-treated mice following DSS treatment compared with DSS-treated control mice, but the overall efficacy of "Amanlac" probiotics was significantly improved than conventional concentration of probiotics. In conclusion, the administration of higher concentrated probiotics helps to successfully maintain intestinal homeostasis, while also improving intestinal inflammation.